Ilya Tsimafeyeu1, Tatiana Zolotareva2, Sergei Varlamov3, Ruslan Zukov4, Vladislav Petkau5, Mikhail Mazhbich6, Galina Statsenko7, Sufia Safina8, Igor Zaitsev9, Dina Sakaeva10, Alexander Popov11, Pavel Borisov12, Liubov Vladimirova13. 1. Kidney Cancer Research Bureau, Moscow, Russia. Electronic address: tsimafeyeu@gmail.com. 2. Department of Medical Oncology, Samara Regional Clinical Oncology Center, Samara, Russia. 3. Department of Oncourology, Altai Regional Cancer Center, Barnaul, Russia. 4. Department of Oncourology, A.I. Kryzhanovsky Krasnoyarsk Cancer Center, Krasnoyarsk, Russia. 5. Outpatient Department, Sverdlovsk Regional Oncological Dispensary, Ekaterinburg, Russia. 6. Department of Oncourology, Omsk Regional Cancer Center, Omsk, Russia. 7. Department of Medical Oncology, Omsk Regional Cancer Center, Omsk, Russia. 8. Department of Chemotherapy No. 3, Tatarstan Republican Clinical Oncology Dispensary, Kazan, Russia. 9. Department of Urology, Astrakhan Regional Cancer Center, Astrakhan, Russia. 10. Department of Chemotherapy, Republican Clinical Oncology Center, Ufa, Russia. 11. Department of Urology, Obninsk Medical Radiological Research Center, Obninsk, Russia. 12. Outpatient Department, Saint Petersburg City Clinical Oncology Center, Saint Petersburg, Russia. 13. Department of Antitumor Drug Therapy, Rostov Research Institute of Oncology, Rostov-on-Don, Russia.
Abstract
BACKGROUND: The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapy for mRCC and assess the 5-year OS in the Russian population. PATIENT AND METHODS: Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St. Petersburg, and Ufa). Patients were included if mRCC had been diagnosed from January 2010 to January 2011. Anonymized data were collected through an online registry covering the demographic data, treatments, and outcomes. RESULTS: A total of 439 adult mRCC patients were included in the present study for analysis. The mean age at diagnosis of mRCC was 60.9 years (range, 33-90 years; with 9% of patients aged ≥ 75 years). The patients were predominantly men (70.2%) and 67.7% had nephrectomy. Clear cell and non-clear cell tumors were detected in 61.1% and 7.7% of patients, respectively. A total of 271 patients (62%) received systemic therapy. The median duration of therapy was 11 months (95% confidence interval, 9.5-12.5 months). Most treatment was with interferon only (n = 145); 105 patients (23.9%) received targeted therapy, and 69 patients (15.7%) received ≥ 2 treatment lines. The 1-, 3-, and 5-year OS rate was 49.4%, 18.9%, and 8.2%, respectively. The median OS from the start of treatment was 12 months (95% confidence interval, 9.7-14.4 months). CONCLUSION: RENSUR5 is a large real-world database assessing the mRCC treatment patterns and 5-year OS in Russia. According to the first results of the present study, we believe that 5-year OS should improve with novel therapies. The limited administration of targeted therapies was reflected by the results of the 5-year survival rate. The treatment of mRCC has changed in the past years with new treatment options significantly improving OS. The 5-year OS of patients treated with immunotherapy and targeted therapy should be analyzed in the real world.
BACKGROUND: The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapy for mRCC and assess the 5-year OS in the Russian population. PATIENT AND METHODS: Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St. Petersburg, and Ufa). Patients were included if mRCC had been diagnosed from January 2010 to January 2011. Anonymized data were collected through an online registry covering the demographic data, treatments, and outcomes. RESULTS: A total of 439 adult mRCC patients were included in the present study for analysis. The mean age at diagnosis of mRCC was 60.9 years (range, 33-90 years; with 9% of patients aged ≥ 75 years). The patients were predominantly men (70.2%) and 67.7% had nephrectomy. Clear cell and non-clear cell tumors were detected in 61.1% and 7.7% of patients, respectively. A total of 271 patients (62%) received systemic therapy. The median duration of therapy was 11 months (95% confidence interval, 9.5-12.5 months). Most treatment was with interferon only (n = 145); 105 patients (23.9%) received targeted therapy, and 69 patients (15.7%) received ≥ 2 treatment lines. The 1-, 3-, and 5-year OS rate was 49.4%, 18.9%, and 8.2%, respectively. The median OS from the start of treatment was 12 months (95% confidence interval, 9.7-14.4 months). CONCLUSION: RENSUR5 is a large real-world database assessing the mRCC treatment patterns and 5-year OS in Russia. According to the first results of the present study, we believe that 5-year OS should improve with novel therapies. The limited administration of targeted therapies was reflected by the results of the 5-year survival rate. The treatment of mRCC has changed in the past years with new treatment options significantly improving OS. The 5-year OS of patients treated with immunotherapy and targeted therapy should be analyzed in the real world.
Authors: Olga V Kovaleva; Polina Podlesnaya; Maxim Sorokin; Valeria Mochalnikova; Vladimir Kataev; Yuriy A Khlopko; Andrey O Plotnikov; Ivan S Stilidi; Nikolay E Kushlinskii; Alexei Gratchev Journal: Biomedicines Date: 2022-06-27